Verus Capital Partners’s Novo Nordisk NVO Stock Holding History

Verus Capital Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,027	Closed	-$205K	–	489
2025 Q4	$205K	Sell	4,027 -503	-11%	-$25.7K	0.01%	427
2025 Q3	$251K	Sell	4,530 -1,454	-24%	-$85.1K	0.02%	353
2025 Q2	$413K	Buy	5,984 +2,296	+62%	+$156K	0.04%	238
2025 Q1	$256K	Sell	3,688 -201	-5%	-$16.6K	0.03%	304
2024 Q4	$326K	Sell	3,889 -1,334	-26%	-$144K	0.03%	264
2024 Q3	$622K	Buy	5,223 +748	+17%	+$99.8K	0.06%	169
2024 Q2	$637K	Sell	4,475 -1,014	-18%	-$134K	0.07%	164
2024 Q1	$705K	Sell	5,489 -665	-11%	-$79.2K	0.08%	149
2023 Q4	$637K	Buy	6,154 +1,507	+32%	+$149K	0.08%	143
2023 Q3	$423K	Buy	+4,647	New	+$409K	0.06%	182
2020 Q1	$78K	Hold	2,600	–	–	0.02%	372
2019 Q4	$75K	Buy	+2,600	New	+$72K	0.02%	469

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Verus Capital Partners's NVO Position: Q1 2026 in Review

Verus Capital Partners sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 4,027 shares — an estimated $205K sold.

Verus Capital Partners first reported a position in NVO in Q4 2019 and held it in 12 quarters. The position peaked at $705K in Q1 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Verus Capital Partners reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
Verus Capital Partners sold 4,027 Novo Nordisk shares in Q1 2026, an estimated $205K.
Verus Capital Partners first reported a position in Novo Nordisk in Q4 2019 and held it in 12 quarters.
Verus Capital Partners's Novo Nordisk position peaked at $705K in Q1 2024.
1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Verus Capital Partners's 13F filing for Q1 2026, filed 22 May 2026.